Check Before You Invest : Bafna Pharmaceuticals Ltd

Snapshot

Q.1 Which industry/sub-sector does Bafna Pharmaceuticals Ltd belong to?

Bafna Pharmaceuticals Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.2 Is Bafna Pharmaceuticals Ltd a good quality company?

Bafna Pharmaceuticals Ltd is a weak quality company, based on a inconsistent 10-year financial track record.

Q.3 Is Bafna Pharmaceuticals Ltd undervalued or overvalued?

Bafna Pharmaceuticals Ltd appears Somewhat overvalued, as its key valuation ratios are above with their past averages.

Q.4 Is Bafna Pharmaceuticals Ltd a good buy now?

Bafna Pharmaceuticals Ltd is a good buy now, based on strong price trend analysis suggesting prices may rise. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Bafna Pharmaceuticals Ltd?

Bafna Pharmaceuticals Ltd revenue growth is -4.3% for FY-2025, which is below its 5-year CAGR of 27.99%, indicating slower growth.

Q.2 Return on capital employed (ROCE) of Bafna Pharmaceuticals Ltd?

Bafna Pharmaceuticals Ltd Return on capital employed is 6.31% for FY-2025, which is below its 5-year historical median of 9.56%. The current ROCE is below its estimated weighted average cost of capital (WACC) of 14%, indicating value preservation.

Q.3 Return on Asset of Bafna Pharmaceuticals Ltd?

Bafna Pharmaceuticals Ltd Return on Asset is 2.76%, which is below its 5-year historical median of 5.91%, indicating deteriorated asset utilization efficiency.

Q.4 Return on Equity (ROE) of Bafna Pharmaceuticals Ltd?

Bafna Pharmaceuticals Ltd Return on equity is 5.01% for FY-2025, which is below its 5-year historical median of 9.52%, indicating the business is making worse use of its shareholders capital.

Q.5 Cash conversion cycle of Bafna Pharmaceuticals Ltd?

Bafna Pharmaceuticals Ltd Cash conversion cycle is 88 days, above its 5-year historical median of 79 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.

	Current Level	5-year Historic Median
Asset Turnover	0.97	0.97
ROE	5.01	9.52
ROCE	6.31	9.56
Cash Conversion Cycle	88 days	79 days

Q.6 Gross Profit margin of Bafna Pharmaceuticals Ltd?

Bafna Pharmaceuticals Ltd Gross profit margin which is the profit after deduction of direct costs, is 7.7% for FY-2025, which is below its 5-year median of 14.5%, indicating decreasing margins.

Q.7 Operating Profit Margin of Bafna Pharmaceuticals Ltd?

Bafna Pharmaceuticals Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 7.51% for FY-2025, which is below its 5-year median of 13.62% indicating decreasing margins.

Q.8 Net Profit Margin of Bafna Pharmaceuticals Ltd?

Bafna Pharmaceuticals Ltd Net Profit Margin is 2.85% for FY-2025, is below with its 5-year median of 6.13%, indicating decreasing margins.

	Current Level	5-year Historic Median
Gross Profit Margin	7.7	14.5
Operating Profit Margin	7.51	13.62
Net Profit Margin	2.85	6.13

Q.9 Debt to Equity ratio of Bafna Pharmaceuticals Ltd?

Bafna Pharmaceuticals Ltd Debt-to-Equity ratio is 0.33, which is above with the industry average of 0.27, indicating higher debt levels in the industry.

Q.10 Debt to cash flow from operations of Bafna Pharmaceuticals Ltd?

Bafna Pharmaceuticals Ltd Debt to cash flow from operations is 1.27, which is at a healthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Bafna Pharmaceuticals Ltd?

Promoters hold 75.00% of the Bafna Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Bafna Pharmaceuticals Ltd vs industry peers?

Bafna Pharmaceuticals Ltd revenue CAGR is 27.99%, compared to the industry median CAGR of 8.30%, indicating faster growth and gaining its market share.

Profit Metrics

	Current Level	5-year Industry Median
Revenue Growth	-4.3	8.3
Gross Profit Growth	-8.3	14.7
Operating Profit Growth	-	11.4
Net Profit Growth	-42.9	NAN

Operating Efficiency

	Current Level	5-year Industry Median
Asset Turnover	0.97	0.81
ROE	5.01	9.49
ROCE	6.31	11.91
Cash Conversion Cycle (days)	87.97	85

Valuation & price assessment

Q.1 Stock return of Bafna Pharmaceuticals Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 15.8% based on the current price.

Q.2 What return has the stock given over the last decade?

	9Y	5Y	3Y	1Y
Share Price CAGR	15.8%	-1.8%	16.7%	87%

Q.3 Valuation ratios of Bafna Pharmaceuticals Ltd vs historical?

The current P/E is lower that its historical median.

Q.4 How do the current valuation ratios compare with 5-year historical median and industry numbers?

Valuation Ratios	Current	5-year Historic Median	5-year Industry Median
Price to Earnings	33.65	42.24	31.09
Price to Book	3.5	3.16	2.85
Price to Sales	2.21	2.18	2.79
EV to EBITDA	18.3	18.81	15.87

Check more companies

5. Wockhardt

9. Pfizer

10. Neuland Laboratories

Check trending companies

1. JSW Infrastructure Ltd.

2. Aditya Birla Fashion and Retail Ltd.

3. Zydus Lifesciences Ltd.

4. Techno Electric & Engineering Company Ltd.

5. Cello World Ltd.